Pathologica Ltd

	Page
Balance Sheet	1—2
Notes to the Financial Statements	3—5

Registered number: 13100286

		2024		2023
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	4		1,377		2,210

			1,377		2,210
CURRENT ASSETS
Cash at bank and in hand		107		464

		107		464
Creditors: Amounts Falling Due Within One Year	5	(15,659 )		(13,539 )

NET CURRENT ASSETS (LIABILITIES)			(15,552 )		(13,075 )

TOTAL ASSETS LESS CURRENT LIABILITIES			(14,175 )		(10,865 )

NET LIABILITIES			(14,175 )		(10,865 )

CAPITAL AND RESERVES
Called up share capital	6		360		360
Profit and Loss Account			(14,535 )		(11,225 )

SHAREHOLDERS' FUNDS			(14,175)		(10,865)

Page 1

Page 2

Pathologica Ltd

Balance Sheet (continued)

As At 31 December 2024

For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Timothy Scase

Director

21/08/2025

The notes on pages 3 to 4 form part of these financial statements.

1. General Information

Pathologica Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13100286 . The registered office is Paulton House Old Mills, Paulton, Bristol, BS39 7SX.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Going Concern Disclosure

The company has net liabilities. The accounts have been prepared on a going concern basis on the basis that the directors will continue to support the company.

2.3. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Plant & Machinery

20% straight line basis

2.4. Financial Instruments

The entity has only entered into basic financial instruments. Basic financial instruments are recognised at amortised cost, except for investments in nonconvertible preference and non-puttable ordinary shares which are measured at fair value, with changes recognised in profit or loss.

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

2.5. Estimates and Judgements

There were no critical accounting estimates or judgements required in the preparation of these financial statements in the current or prior year.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 2 (2023: 2)

Page 3

Page 4

Pathologica Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2024

4. Tangible Assets

	Plant & Machinery
	£
Cost
As at 1 January 2024	4,166

As at 31 December 2024	4,166

Depreciation
As at 1 January 2024	1,956
Provided during the period	833

As at 31 December 2024	2,789

Net Book Value
As at 31 December 2024	1,377

As at 1 January 2024	2,210

5. Creditors: Amounts Falling Due Within One Year

	2024	2023
	£	£
Other creditors	15,159	13,039
Accruals and deferred income	500	500

	15,659	13,539

6. Share Capital

	2024	2023
Allotted, called up and fully paid	£	£
120 Ordinary A shares of £ 1 each	120	120
120 Ordinary B shares of £ 1 each	120	120
120 Ordinary C shares of £ 1 each	120	120

	360	360

Prescribed particulars

Class of Shares: A

The 'A' ordinary shares have attached to them full voting and capital distribution, including on winding up, rights are not redeemable. The holders of the 'A' ordinary shares, shall rank pari passu with regard to entitlement to dividend except that the directors may at any time resolve to declare either dividend payments of different amounts payable on each class of share or a dividend payable on one or the other class of share to the exclusion of the other class.

Class of Shares: B

The 'B' ordinary shares have attached to them full voting and capital distribution, including on winding up, rights are not redeemable. The holders of the 'B' ordinary shares, shall rank pari passu with regard to entitlement to dividend except that the directors may at any time resolve to declare either dividend payments of different amounts payable on each class of share or a dividend payable on one or the other class of share to the exclusion of the other class.

...CONTINUED

Page 4

Page 5

Pathologica Ltd

Notes to the Financial Statements (continued)

For The Year Ended 31 December 2024

6. Share Capital - continued

Class of Shares: C

The 'C' ordinary shares have attached to them full voting and capital distribution, including on winding up, rights are not redeemable. The holders of the 'C' ordinary shares, shall rank pari passu with regard to entitlement to dividend except that the directors may at any time resolve to declare either dividend payments of different amounts payable on each class of share or a dividend payable on one or the other class of share to the exclusion of the other class.

Page 5